The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation

被引:166
作者
Finch, A. [1 ]
Metcalfe, K. A. [1 ,2 ]
Chiang, J. K. [1 ]
Elit, L. [3 ]
McLaughlin, J. [4 ]
Springate, C. [5 ]
Demsky, R. [6 ]
Murphy, J. [6 ,7 ]
Rosen, B. [6 ,7 ]
Narod, S. A. [1 ]
机构
[1] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada
[2] Univ Toronto, Bloomberg Sch Nursing, Toronto, ON M5S 1A1, Canada
[3] McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON, Canada
[4] Samuel Lunenfeld Res Inst, Toronto, ON, Canada
[5] BC Canc Agcy, Vancouver, BC, Canada
[6] Princess Margaret Hosp, Familial Breast & Ovarian Canc Clin, Toronto, ON M4X 1K9, Canada
[7] Univ Toronto, Univ Hlth Network, Dept Gynecol Oncol, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
Salpingo-oophorectomy; BRCA1; BRCA2; Menopausal symptoms; Sexual functioning; QUALITY-OF-LIFE; BREAST-CANCER RISK; HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; ESTROGEN THERAPY; OVARIAN; TESTOSTERONE; ANDROGEN; QUESTIONNAIRE;
D O I
10.1016/j.ygyno.2010.12.326
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objective. Prophylactic salpingo-oophorectomy is recommended to women who carry a BRCA1 or BRCA2 mutation to reduce the risks of breast, ovarian and fallopian tube cancer. We measured the impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual functioning in women with a BRCA mutation. Methods. Women who underwent prophylactic salpingo-oophorectomy between October 1, 2002 and June 26, 2008 for a known BRCA1 or BRCA2 mutation were invited to participate. Participants completed questionnaires before prophylactic surgery and again one year after surgery. Measures of sexual functioning and menopausal symptoms before and after surgery were compared. Satisfaction with the decision to undergo prophylactic salpingo-oophorectomy was evaluated. Results. 114 women who underwent prophylactic surgery completed questionnaires before and one year after surgery. Subjects who were premenopausal at the time of surgery (n = 75) experienced a significant worsening of vasomotor symptoms (hot flashes, night sweats and sweating) and a decline in sexual functioning (desire, pleasure, discomfort and habit). The increase in vasomotor symptoms and the decline in sexual functioning were mitigated by HRT, but symptoms did not return to pre-surgical levels. HRT decreased vaginal dryness and dyspareunia; however, the decrease in sexual pleasure was not alleviated by HRT. Satisfaction with the decision to undergo prophylactic salpingo-oophorectomy remained high regardless of increased vasomotor symptoms and decreased sexual function. Conclusions. Women who undergo prophylactic salpingo-oophorectomy prior to menopause experience an increase in vasomotor symptoms and a decrease in sexual functioning. These symptoms are improved by HRT, but not to pre-surgical levels. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:163 / 168
页数:6
相关论文
共 42 条
[1]
[Anonymous], 1995, JAMA, V273, P491
[2]
[Anonymous], 2008, Obstetrics and Gynecology, V111, P231
[3]
Endogenous sex hormones, breast cancer risk, and tamoxifen response: An ancillary study in the NSABP Breast Cancer Prevention Trial (P-1) [J].
Beattie, MS ;
Costantino, JP ;
Cummings, SR ;
Wickerham, DL ;
Vogel, VG ;
Dowsett, M ;
Folkerd, EJ ;
Willett, WC ;
Wolmark, N ;
Hankinson, SE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (02) :110-115
[4]
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer [J].
Bines, J ;
Oleske, DM ;
Cobleigh, MA .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1718-1729
[5]
The effect of hysterectomy and bilaterally salpingo-oophorectomy on sexual function in post-menopausal women [J].
Celik, Husnu ;
Gurates, Bilgin ;
Yavuz, Adem ;
Nurkalem, Cemile ;
Hanay, Fethi ;
Kavak, Burcin .
MATURITAS, 2008, 61 (04) :358-363
[6]
TESTOSTERONE ENHANCES ESTRADIOLS EFFECTS ON POSTMENOPAUSAL BONE-DENSITY AND SEXUALITY [J].
DAVIS, SR ;
MCCLOUD, P ;
STRAUSS, BJG ;
BURGER, H .
MATURITAS, 1995, 21 (03) :227-236
[7]
Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy [J].
Dimitrakakis, C ;
Jones, RA ;
Liu, A ;
Bondy, CA .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2004, 11 (05) :531-535
[8]
Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606
[9]
Breast cancer risk following bilateral oophorectorny in BRCA1 and BRCA2 mutation carriers:: An international case-control study [J].
Eisen, A ;
Lubinski, J ;
Klijn, J ;
Moller, P ;
Lynch, HT ;
Offit, K ;
Weber, B ;
Rebbeck, T ;
Neuhausen, SL ;
Ghadirian, P ;
Foulkes, WD ;
Gershoni-Baruch, R ;
Friedman, E ;
Rennert, G ;
Wagner, T ;
Isaacs, C ;
Kim-Sing, C ;
Ainsworth, P ;
Sun, P ;
Narod, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7491-7496
[10]
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers [J].
Eisen, Andrea ;
Lubinski, Jan ;
Gronwald, Jacek ;
Moller, Pal ;
Lynch, Henry T. ;
Klijn, Jan ;
Kim-Sing, Charmaine ;
Neuhausen, Susan L. ;
Gilbert, Lucy ;
Ghadirian, Parviz ;
Manoukian, Siranoush ;
Rennert, Gad ;
Friedman, Eitan ;
Isaacs, Claudine ;
Rosen, Eliot ;
Rosen, Barry ;
Daly, Mary ;
Sun, Ping ;
Narod, Steven A. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (19) :1361-1367